Drug Safety

, Volume 32, Issue 3, pp 187–202 | Cite as

Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes

An Overview of Data from PROactive
  • John Dormandy
  • Mondira Bhattacharya
  • Anne-Ruth van Troostenburg de Bruyn
  • on behalf of the PROactive investigators
Review Article

Abstract

People with type 2 diabetes mellitus have an excess risk of macrovascular disease and a poorer prognosis. PROactive (PROspective pioglitAzone Clinical Trial In macro Vascular Events) was a landmark study of secondary cardiovascular disease (CVD) prevention in type 2 diabetes that suggested a beneficial effect of pioglitazone therapy on macrovascular outcomes. Previous studies have already shown that pioglitazone has a good safety and tolerability profile in people with type 2 diabetes, but PROactive provided an opportunity to assess tolerability and safety associated with long-term exposure in a vulnerable subpopulation at very high cardiovascular risk. This review discusses all the key safety and tolerability characteristics associated with pioglitazone therapy in PROactive.

As in previous studies, pioglitazone was associated with typical, but manageable, increases in oedema (26.4% vs 15.1% for placebo) and weight gain (mean change of +3.8 kg vs −0.6 kg for placebo). Increased hypoglycaemia with pioglitazone was consistent with improved glycaemic control. Despite more reports of serious heart failure in the pioglitazone group (5.7% vs 4.1% for placebo), there was a proportional improvement in macrovascular outcomes among patients developing heart failure, and absolute rates of macro-vascular events and mortality were similar to those in the placebo group. Liver function tests confirmed the hepatic safety of pioglitazone with long-term use and revealed a tendency to improved hepatic function, which may reflect reductions in liver fat. The comparative incidence of malignancies was similar; however, more cases of bladder neoplasm (14 vs 5) and fewer cases of breast cancer (3 vs 11) were observed in the pioglitazone versus placebo arms of the study. A higher rate of bone fractures observed among pioglitazone-treated female patients (5.1% vs 2.5%) warrants further investigation. Overall, safety and tolerability was predictable, and adverse events were not treatment limiting. These results suggest that any beneficial effects of pioglitazone on macrovascular outcomes are accompanied by good long-term tolerability in this population of very high-risk patients with type 2 diabetes and established CVD.

Notes

Acknowledgements

The authors would like to thank Absolute Healthcare Communications for editorial assistance. Funding for this assistance was provided by Takeda Pharmaceuticals.

PROactive was funded by Takeda Europe R&D Centre Ltd, London, UK, and Eli Lilly and Company, Indianapolis, IN, USA. The study was designed by the International Steering Committee, who approved the protocol and amendments. The commercial sponsor of PROactive had two representatives on the International Steering Committee and the same two were also members of the Executive Committee. Access to data was given freely to the Executive Committee and authors and the sponsors have not suppressed any data. Data interpretation, writing of this report and the decision to publish was made by all of the authors.

Professor Dormandy is a member of the Executive Committee. Drs Bhattacharya and van Troostenburg de Bruyn are employees of Takeda Global Research & Development.

References

  1. 1.
    Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998 Jul; 339(4): 229–34PubMedCrossRefGoogle Scholar
  2. 2.
    Idris I, Thomson GA, Sharma JC. Diabetes mellitus and stroke. Int J Clin Pract 2006; 60(1): 48–56PubMedCrossRefGoogle Scholar
  3. 3.
    Juutilainen A, Lehto S, Rönnemaa T, et al. Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects. Diabetes Care 2005; 28(12): 2901–7PubMedCrossRefGoogle Scholar
  4. 4.
    National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 Dec; 106: 3143–421Google Scholar
  5. 5.
    Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998 Jan; 21(1): 69–75PubMedCrossRefGoogle Scholar
  6. 6.
    Mukamal KJ, Nesto RW, Cohen MC, et al. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care 2001 Aug; 24(8): 1422–7PubMedCrossRefGoogle Scholar
  7. 7.
    Roper NA, Bilous RW, Kelly WF, et al. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal population based study. BMJ 2001 Jun; 322(7299): 1389–93PubMedCrossRefGoogle Scholar
  8. 8.
    Dormandy JA, Charbonnel B, Eckland DJ, et al., PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro-Vascular Events): a randomised controlled trial. Lancet 2005 Oct; 366: 1279–89PubMedCrossRefGoogle Scholar
  9. 9.
    Betteridge DJ, DeFronzo RA, Chilton RJ. PROactive: time for a critical appraisal. Eur Heart J 2008 Apr; 29(8): 969–83 201PubMedCrossRefGoogle Scholar
  10. 10.
    Wilcox R, Kupfer S, Erdmann E, PROactive Study investigators. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J 2008 Apr; 155(4): 712–7PubMedCrossRefGoogle Scholar
  11. 11.
    Erdmann E, Dormandy JA, Charbonnel B, et al., PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. Results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007; 49(17): 1772–80PubMedCrossRefGoogle Scholar
  12. 12.
    Wilcox R, Bousser MG, Betteridge DJ, et al., PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007 Sep; 38: 865–73PubMedCrossRefGoogle Scholar
  13. 13.
    Massi-Benedetti M, Scheen A, Charbonnel B. Pioglitazone delays the need for permanent insulin use: results from PROactive [abstract]. Diabetes 2006; 55: A124Google Scholar
  14. 14.
    Charbonnel B, Dormandy J, Erdmann E, et al., PROactive Study Group. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004 Jul; 27(7): 1647–53PubMedCrossRefGoogle Scholar
  15. 15.
    Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract 2007 May; 76(2): 279–89PubMedCrossRefGoogle Scholar
  16. 16.
    Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione-use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004 Jan; 27: 256–63PubMedCrossRefGoogle Scholar
  17. 17.
    Raskin P, Rendell M, Riddle MC, et al., Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001 Jul; 24: 1226–32PubMedCrossRefGoogle Scholar
  18. 18.
    Rosenstock J, Einhorn D, Hershon K, et al., Pioglitazone 014 Study Group. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002 May; 56: 251–7PubMedGoogle Scholar
  19. 19.
    Tang WHW. Do thiazolidinediones cause heart failure? A critical review. Cleve Clin J Med 2006 Jun; 73(4): 390–7PubMedCrossRefGoogle Scholar
  20. 20.
    Scheen A, Charbonnel B. Reduced insulin requirements and improved glycemic control with pioglitazone in insulin-treated patients with type 2 diabetes: results from PROactive [abstract]. Diabetes 2006; 55 Suppl. 2: A134Google Scholar
  21. 21.
    Nichols GA, Gullion CM, Koro CE, et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004 Aug; 27: 1879–84PubMedCrossRefGoogle Scholar
  22. 22.
    Bell DS. Heart failure in the diabetic patient. Cardiol Clin 2007; 25: 523–38PubMedCrossRefGoogle Scholar
  23. 23.
    Masoudi FA, Inzucchi SE. Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy. Am J Cardiol 2007; 99(4A): 113–32BCrossRefGoogle Scholar
  24. 24.
    Fang ZY, Schull-Meade R, Downey M, et al. Determinants of subclinical diabetic heart disease. Diabetologia 2005; 48: 394–402PubMedCrossRefGoogle Scholar
  25. 25.
    Fang ZY, Schull-Meade R, Leano R, et al. Screening for heart disease in diabetic subjects. Am Heart J 2005; 149: 349–54PubMedCrossRefGoogle Scholar
  26. 26.
    Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007 Aug; 38: 2148–53CrossRefGoogle Scholar
  27. 27.
    Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007 Sep; 370(9593): 1129–36PubMedCrossRefGoogle Scholar
  28. 28.
    Erdmann E, Wilcox RG. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur Heart J 2008; 29: 12–20PubMedCrossRefGoogle Scholar
  29. 29.
    Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone versus glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008 Apr 2; 299(13): 1561–73PubMedCrossRefGoogle Scholar
  30. 30.
    Erdmann E, Charbonnel B, Wilcox RG, et al., PROactive investigators. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007 Nov; 30: 2773–8PubMedCrossRefGoogle Scholar
  31. 31.
    Rydén L, Thráinsdóttir I, Swedberg K. Adjudication of serious heart failure in patients from PROactive [letter]. Lancet 2007; 368: 189–90CrossRefGoogle Scholar
  32. 32.
    Giles T, Miller A, Elkayam U, et al. Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J Cardiac Failure 2008 Aug; 14(6): 445–52CrossRefGoogle Scholar
  33. 33.
    Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005; 111: 583–90PubMedCrossRefGoogle Scholar
  34. 34.
    Aguilar D, Bozkurt B, Pritchett A, et al. The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J Am Coll Cardiol 2007 Jul 3; 50(1): 32–6PubMedCrossRefGoogle Scholar
  35. 35.
    Schwartz AV, Sellmeyer DE. Thiazolidinedione therapy gets complicated: is bone loss the price of improved insulin resistance? Diabetes Care 2007 Jun; 30: 1670–1PubMedCrossRefGoogle Scholar
  36. 36.
    Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008 May; 31(5): 845–51PubMedCrossRefGoogle Scholar
  37. 37.
    Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008 Apr 28; 168(8): 820–5PubMedCrossRefGoogle Scholar
  38. 38.
    Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 2008 Feb; 19(2): 129–37PubMedCrossRefGoogle Scholar
  39. 39.
    Short R. Fracture risk is a class effect of glitazones. BMJ 2007 Mar; 334(7593): 551PubMedCrossRefGoogle Scholar
  40. 40.
    Heine R, Schindhelm R, Diamant M. Long-term pioglitazone treatment improves markers of liver function: results from PROactive [abstract]. Diabetes 2006; 55 Suppl. 1: A115Google Scholar
  41. 41.
    Belcher G, Schernthaner G. Changes in liver tests during 1-year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabet Med 2005 Aug; 22: 973–9PubMedCrossRefGoogle Scholar
  42. 42.
    Belcher G, Lambert C, Edwards G, et al. Safety and tolerability of pioglitazone, metformin, and gliclazide in the 202 treatment of type 2 diabetes. Diabetes Res Clin Pract 2005 Oct; 70: 53–62PubMedCrossRefGoogle Scholar
  43. 43.
    Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006 Nov; 355: 2297–307PubMedCrossRefGoogle Scholar
  44. 44.
    Schindhelm RK, Diamant M, Dekker JM, et al. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 2006 Nov–Dec; 22: 437–43PubMedCrossRefGoogle Scholar
  45. 45.
    Ono M, Ikegami H, Fujisawa T, et al. Improvement of liver function parameters in patients with type 2 diabetes treated with thiazolidinediones. Metabolism 2005 Apr; 54(4): 529–32PubMedCrossRefGoogle Scholar
  46. 46.
    Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004 Jan; 39: 188–96PubMedCrossRefGoogle Scholar
  47. 47.
    Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002 Jun; 87(6): 2784–91PubMedCrossRefGoogle Scholar
  48. 48.
    Bajaj M, Suraamornkul S, Pratipanawatr T, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003 Jun; 52(6): 1364–70PubMedCrossRefGoogle Scholar
  49. 49.
    Rajagopalan R, Iyer S, Perez A. Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone. Diabetes Obes Metab 2005 Mar; 7: 161–9PubMedCrossRefGoogle Scholar
  50. 50.
    Takeda Pharmaceutical Company Limited. Actos (pioglitazone hydrochloride) US package insert. Osaka: Takeda, 2004 AugGoogle Scholar
  51. 51.
    Nakashiro K, Hayashi Y, Kita A, et al. Role of peroxisome proliferator-activated receptor and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol 2001 Aug; 159(2): 591–7PubMedCrossRefGoogle Scholar
  52. 52.
    Charbonnel B, Birkeland K, Scheen A. Pioglitazone add-on to either metformin or sulfonylurea: glycaemic results from PROactive [abstract]. Diabet Med 2006; 23: 298Google Scholar
  53. 53.
    Charbonnel B, Scheen A. Pioglitazone in triple oral therapy: long-term glycemic results from PROactive [abstract]. Diabetes 2006; 55 Suppl. 2: A106Google Scholar
  54. 54.
    Basu A, Jensen MD, McCann F, et al. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 2006 Mar; 29: 510–4PubMedCrossRefGoogle Scholar
  55. 55.
    Hollenberg NK. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med 2003 Dec; 115: 111S–5SPubMedCrossRefGoogle Scholar
  56. 56.
    Makimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type 2 diabetes mellitus. Diabetologia 1999 Apr; 42: 406–12PubMedCrossRefGoogle Scholar
  57. 57.
    Derosa G, Cicero AF, Dangelo A, et al. Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens Res 2005a Nov; 28(11): 917–24CrossRefGoogle Scholar
  58. 58.
    Derosa G, Cicero AF, Gaddi A, et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 2005 Jul; 69(1): 5–13PubMedCrossRefGoogle Scholar
  59. 59.
    Goldberg RB, Kendall DM, Deeg MA, et al., GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005 Jul; 28(7): 1547–54PubMedCrossRefGoogle Scholar
  60. 60.
    Marx N, Wohrle J, Nusser T, et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 2005 Nov; 112(18): 2792–8PubMedCrossRefGoogle Scholar
  61. 61.
    Miyazaki Y, Mahankali A, Wajcberg E, et al. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004 Sep; 89(9): 4312–9PubMedCrossRefGoogle Scholar
  62. 62.
    Perez A, Khan M, Johnson T, et al. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. Diab Vasc Dis Res 2004 May; 1(1): 44–50PubMedCrossRefGoogle Scholar
  63. 63.
    Pfutzner A, Marx N, Lubben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005; 45(12): 1925–31PubMedCrossRefGoogle Scholar
  64. 64.
    Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003 Sep; 26(9): 2493–9PubMedCrossRefGoogle Scholar
  65. 65.
    Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–71PubMedCrossRefGoogle Scholar
  66. 66.
    Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007 Sep; 298: 1189–95PubMedCrossRefGoogle Scholar
  67. 67.
    Karter AJ, Ahmed AT, Liu J, et al. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 2005 Aug; 22(8): 986–93PubMedCrossRefGoogle Scholar
  68. 68.
    Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007 Sep; 298: 1180–8PubMedCrossRefGoogle Scholar
  69. 69.
    Gerrits CM, Bhattacharya M, Manthena S, et al. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 2007 Oct; 16(10): 1065–71PubMedCrossRefGoogle Scholar
  70. 70.
    Lipscombe LL, Gomes T, Lévesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007 Dec 12; 298(22): 2634–43PubMedCrossRefGoogle Scholar
  71. 71.
    Spanheimer R, Perez A, Kupfer S, et al. Effects of pioglitazone versus glyburide on markers of liver safety: results from a 3-year, randomized, double-blind trial [abstract]. Diabetes 2006; 55 Suppl. 1: A75Google Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • John Dormandy
    • 1
  • Mondira Bhattacharya
    • 2
  • Anne-Ruth van Troostenburg de Bruyn
    • 2
  • on behalf of the PROactive investigators
  1. 1.Department of Clinical Vascular Research, Ingelby HouseSt George’s HospitalLondonUK
  2. 2.Takeda Global Research & Development (Europe) LtdLondonUK

Personalised recommendations